# First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

> **NCT04417465** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 101 (actual)

## Conditions studied

- Advanced Solid Tumors Cancer

## Interventions

- **DRUG:** ABBV-CLS-579
- **DRUG:** PD-1 inhibitor
- **DRUG:** VEGFR TKI

## Key facts

- **NCT ID:** NCT04417465
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-03
- **Primary completion:** 2025-08-21
- **Final completion:** 2025-08-21
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417465, "First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04417465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*